The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis.

Wilson, E C F

The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. [electronic resource] - Rheumatology (Oxford, England) Jul 2007 - 1096-101 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1462-0324

10.1093/rheumatology/kem054 doi


Acute Disease
Computer Simulation
Cost-Benefit Analysis
Cyclophosphamide--administration & dosage
Day Care, Medical--economics
Drug Costs
Humans
Immunosuppressive Agents--economics
Infusions, Intravenous
Lupus Erythematosus, Systemic--drug therapy
Lupus Nephritis--drug therapy
Models, Economic
Mycophenolic Acid--analogs & derivatives
Prednisolone--economics
Quality-Adjusted Life Years
State Medicine--economics